Lumera Teams With The Institute for Systems Biology to Accelerate Proteomic Research

Collaboration to Utilize ISB's High Throughput Technologies and Lumera's New

High Throughput, Label-Free Detection System for the Proteomics Market

Feb 14, 2005, 00:00 ET from Lumera Corporation

    BOTHELL, Wash., Feb. 14 /PRNewswire-FirstCall/ -- Lumera Corporation
 (Nasdaq:   LMRA) and The Institute for Systems Biology (ISB) have agreed to
 collaborate in the development of a high-throughput, label-free detection
 platform designed to revolutionize proteomics research.
     The technology platform consists of Lumera's ProteomicProcessor(TM) and
 NanoCapture(TM) Array technology.  The ProteomicProcessor(TM) tool reads
 Lumera's high density NanoCapture(TM) Microarrays in real-time, without the
 use of molecular labels.  By combining these technologies, researchers will be
 able to isolate, compile and process vast amounts of data at high-speeds to
 accelerate proteomic research.
     Protein-protein, protein-drug, and protein-DNA interactions can be
 measured with the new system.  Real-time kinetics measurements are provided
 for the binding interactions from complex mixtures on thousands of
 user-defined spots on the high density NanoCapture(TM) Microarrays.
     "We are extremely pleased to work with ISB on this exciting proteomics
 project.  We believe that combining NanoCapture(TM) arrays with real-time
 detection will revolutionize the way and the speed at which proteomics
 research is done," said Lumera Chief Executive Officer Tom Mino.  "Our
 intention is to bring this technology to market as a user-definable, open
 platform product family as quickly as possible."
     "By eliminating the need for labels in a high throughput format, Lumera
 has removed one of the major road blocks in protein research," said Stephen
 Lasky, ISB's Director of Technology Development.  "Lumera's
 ProteomicProcessor(TM) has the potential to give us the capability to look at
 large networks of binding interactions while, at the same time, providing us
 with specific interaction kinetics of each individual binding event," Lasky
 continued. "Until now, there has been no feasible method of doing anything
 like this on a systems-wide level."
     About Lumera
     Lumera is an emerging leader in the field of nanotechnology.  The company
 designs proprietary molecular structures and polymer compounds for a broad
 range of bioscience, electro-optic, and specialty nanotechnology applications.
 The company also has developed proprietary processes for fabricating such
 devices. For more information, please visit
     Certain statements contained in this release are forward-looking
 statements that involve a number of risks and uncertainties. Factors that
 could cause actual results to differ materially from those projected in the
 company's forward-looking statements include the following: market acceptance
 of our technologies and products; our ability to obtain financing; our
 financial and technical resources relative to those of our competitors; our
 ability to keep up with rapid technological change; government regulation of
 our technologies; our ability to enforce our intellectual property rights and
 protect our proprietary technologies; the ability to obtain additional
 contract awards and to develop partnership opportunities; the timing of
 commercial product launches; the ability to achieve key technical milestones
 in key products; and other risk factors identified from time to time in the
 company's SEC reports, including in its registrations statement on Form S-1,
 dated July 22, 2004 and its Quarterly Reports on Form 10-Q.

SOURCE Lumera Corporation